Preclinical studies have shown that inhibition of SREBP signaling using fatostatin, a compound which blocks the activity of all forms of SREBP by inhibiting the binding of the SCAP protein to SREBP, suppressing cell proliferation in AR-positive prostate cancer cells, decreasing AR-positive prostate tumor growth, and lowering blood PSA in mice. The gene discussed is AR; the disease is prostate carcinoma.